BiotechTube

gemcitabine + carboplatin + paclitaxel

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epithelial Ovarian Cancer

Conditions

Epithelial Ovarian Cancer

Trial Timeline

Jul 1, 2003 → Apr 1, 2005

NCT ID
NCT00490711

About gemcitabine + carboplatin + paclitaxel

gemcitabine + carboplatin + paclitaxel is a phase 2 stage product being developed by Eli Lilly for Epithelial Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00490711. Target conditions include Epithelial Ovarian Cancer.

What happened to similar drugs?

4 of 13 similar drugs in Epithelial Ovarian Cancer were approved

Approved (4) Terminated (1) Active (9)
✅Olaparib + BevacizumabAstraZenecaApproved
✅intravitreal injection with ranibizumabNovartisApproved
✅AfliberceptRegeneron PharmaceuticalsApproved
✅AfliberceptRegeneron PharmaceuticalsApproved
🔄Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
🔄AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + TopotecanAstraZenecaPhase 3
🔄Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00490711Phase 2Completed
NCT00191256Phase 2Completed

Competing Products

20 competing products in Epithelial Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
LY2228820 + Carboplatin + Placebo + GemcitabineEli LillyPhase 1/2
32
PemetrexedEli LillyPhase 2
35
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
35
Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
40
Carboplatin + Mirvetuximab Soravtansine + BevacizumabAbbViePhase 2
42
Mirvetuximab SoravtansineAbbViePhase 2
42
AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + TopotecanAstraZenecaPhase 3
47
AvelumabAstraZenecaPhase 2
27
Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
40
Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weeklyAstraZenecaPhase 2
31
Olaparib + BevacizumabAstraZenecaApproved
47
Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
40
PembrolizumabMerckPhase 2
42
MK-1775 and carboplatinMerckPhase 2
35
GardasilMerckPhase 1
29
NG-350A plus PembrolizumabMerckPhase 1
29
Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
40
V501MerckPhase 3
40
9-valent HPV vaccinationMerckPhase 2
42